Fernández, Sara
Grafia, Ignacio
Peyrony, Olivier
Canet, Emmanuel
Vigneron, Clara
Monet, Clément
Issa, Nahéma
Decavele, Maxens
Moreau, Anne-Sophie
Lautrette, Alexandre
Lacave, Guillaume
Morel, Guillaume
Cadoz, Cyril
Argaud, Laurent
Statlender, Liran
Azem, Karam
Quenot, Jean-Pierre
Lesieur, Olivier
Fernández, Javier
Farrero, Marta
Marcos, Mª Ángeles
Lemiale, Virgine
Castro, Pedro
Azoulay, Élie
Article History
Received: 18 May 2024
Accepted: 8 July 2024
First Online: 16 July 2024
Declarations
:
: This study was approved by the appropriate French ethics committee (<i>Societé de Réanimation de Langue Française</i>, CE SRLF 22-036,06/07/2022), Spanish ethics committee (<i>Comité de Ética de la Investigación con medicamentos [CEim] del Hospital Clínic de Barcelona</i>, HCB/2022/0333, 31/03/2022), and Israeli ethics committee (Rabin Medical Center Institutional review board [IRB], RMC-0661-22, 16/05/2022). All three ethics committees waived the need for patient informed consent, in compliance with local legislation on retrospective analyses of de-identified health data.
: Not applicable.
: SF has received congress registration fee coverage from Pfizer. OP has received speaker fees from BMS and Qiagen and consultancy fees from Sanofi. EC has received speaker fees and travel and accommodation expense coverage from Gilead, Shionogi BV, and Sanofi-Genzyme. PC has received honoraria for scientific work from Pfizer, MSD, Gilead, Alexion, and AOP Health and consultancy fees from Alexion, Janssen, Gilead, and Sanofi. MD has received congress registration fee coverage from ISIS Medical. EA is an associate editor of Critical Care Journal and has received fees for lectures from Pfizer, Alexion, Sanofi, and Mindray. None of the other authors has any conflicts of interest to declare.